B+
Bull case
25%
Probability
Target price
$52.00
Analysis reference price unavailable
Analysis 2026-05-23 · RankAlpha Sentiment Codex
IMVT
ImmunovantDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The post-print bull case is that the market is willing to look through the widened loss because IMVT-1402 produced strong open-label D2T RA activity, no new safety signals, and enough cash to fund announced indications through a potential GD launch. Stifel was reported to reiterate Buy with a $49 target after the release, reinforcing that some analysts see the data as supporting a higher valuation.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +6.3.
What can break
Batoclimab discontinuation leaves IMVT-1402 as the dominant strategic driver, increasing concentration risk.
Momentum
70
Value
41
Sentiment
55
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $37.00 · Bull $52.00 · Bear $18.00Analysis 2026-05-23; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-23 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $48.88
Why
Momentum70 · Δ7d +3.1
Value41 · Δ7d 0.0
Sentiment55 · Δ7d +6.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +6.3.
Contradictions & invalidation
- • Batoclimab discontinuation leaves IMVT-1402 as the dominant strategic driver, increasing concentration risk.
- • FY26 operating burn rose sharply, with R&D up to $456.7 million and net loss to $505.6 million, so future capital needs remain a risk despite the current cash runway.
- • The bear case remains that batoclimab is being discontinued, FY26 R&D spend rose to $456.7 million, net loss widened to $505.6 million, and the lead asset still needs to prove itself in blinded/registrational settings before the market should assign durable value.
Catalyst clock
2026-05-20
Q4/FY26 earnings release was overshadowed by IMVT-1402 RA data
Lead driver: Sentiment · See AI snapshot
Momentum
70
9% active weight
Current posture
7d trendImproving
Δ7d
+3.1
Δ21d
-16.0
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
55
62% active weight
Current posture
7d trendImproving
Δ7d
+6.3
Δ21d
+14.5
Why this grade
Composite grade D. Momentum 69.8 / Value 41.2 / Sentiment 54.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-23. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$37.00
Analysis reference price unavailable
Analysis 2026-05-23 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-05-23 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$9.03B
Beta
0.54
Shares Out
206.55M
P/E (TTM) · Derived
-15.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-19.40
Rev YoY
-
EPS YoY
+5.6%
Gross Margin
-
Op Margin
-
Net Debt
-$902.04M
Current Ratio
7.27
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data